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The p16 tumour suppressor gene located on chromosome 9p21,
encodes a 16 kDa protein that acts as a cyclin-dependent kinase
(cdk) 4/6 inhibitor (Serrano et al, 1993). This gene, whose locus is
denominated CDKN2A, has also been named MTS1 and p16ink4a
(Kamb et al, 1994a; Ranade et al, 1995). The CDKN2A gene
utilizes alternative first exons and common downstream exons to
encode two structurally unrelated proteins, p16ink4a and p19arf,
which mediate cell cycle arrest through different mechanisms
(Quelle et al, 1995; Stone et al, 1995; Chin et al, 1998).
The progression of proliferating cells through the different
phases of the cell cycle is highly regulated by activators and
inhibitors (Hunter and Pines, 1994). p16 belongs to an important
group of proteins that includes the p15ink4b, p21waf1 and p27kip1,
which negatively regulate the G1 phase of the cell cycle (Serrano
et al, 1993). The p16 gene product binds to cdk4 and cdk6
inhibiting their association with cyclin D1. The inhibition of the
cyclin D1–cdk4/6 complex activity prevents retinoblastoma
protein (pRB) phosphorylation and the release of E2F, leading to
the inhibition of the cell cycle in the G1/S transition (Serrano et al,
1993; Tam et al, 1994; Yeundall and Jakus, 1995). Genetic
abnormalities inactivating the p16 gene might confer cell growth
advantages contributing to the tumorigenic process.
Genetic alterations involving the chromosomal region 9p21–22,
such as translocations, insertions, heterozygous and homozygous
deletions are frequently observed in human cancer. The p16 gene
is considered to be the deletion target in this region (Kamb et al,
1994b; Williamson et al, 1995). High frequencies of homozygous
deletion and mutations of this gene have been detected in cell lines
derived from different types of tumours (glioma, breast cancer,
melanoma, lung, bladder, leukaemia) (Kamb et al, 1994a; Nobori
et al, 1994), suggesting that p16 may play an important role in the
regulation of cellular growth in the majority of cells. However, in
primary tumours, p16 genetic alterations occur frequently in only a
subset of tumour types (Koh et al, 1995; Pollock et al, 1996). The
highest frequencies of p16 inactivation by mutations and homo-
zygous deletions are observed in carcinomas of the pancreas,
oesophagus, renal cell, head and neck and in melanoma (Caldas et
al, 1994; Mori et al, 1994; Cairns et al, 1995; Flores et al, 1996;
Reed et al, 1996). Furthermore, germline p16 mutations predis-
pose to familial melanoma (Hussussian et al, 1994; Kamb et al,
1994b).
Several studies have demonstrated high frequencies of loss of
heterozygosity (LOH) on the short arm of chromosome 9
compared to the p16 mutations found in primary tumours. In addi-
tion, a complex pattern of LOH on 9p21–22 has been observed in
different types of tumours, suggesting that this region may harbour
other tumour suppressor genes associated with the tumorigenic
process (Puig et al, 1995; Farrell et al, 1997; Kim et al, 1997). On
the other hand, de novo methylation has been proposed to be an
important alternative mechanism of p16 gene inactivation. Merlo
et al (1995), studying cell lines and primary solid tumours
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strated that p16 hypermethylation is a common event in those
tumours. Subsequent studies have confirmed that p16 is hyper-
methylated in carcinomas of the breast (31%), colon (40%),
gliomas (44%), oesophageal adenocarcinomas (38%) and multiple
myeloma (75%) (Herman et al, 1995; Fueyo et al, 1996; Lo et al,
1996; Ng et al, 1997; Wong et al, 1997).
Chromosome 9p deletions are considered to play a role in the
early stages of the tumorigenic process of the head and neck
(Califano et al, 1996). High frequencies of LOH of the 9p21–22
chromosomal region have been reported in squamous cell carci-
nomas of the head and neck, including dysplasia and carcinoma in
situ (Nawroz et al, 1994; van der Reit et al, 1994). Analysis of p16
mutations, hypermethylation and homozygous deletions showed
that 7–79% of squamous cell carcinomas of the head and neck had
at least one of those genetic events (Cairns et al, 1994; Zhang et al,
1994; Lydiatt et al, 1995; Reed et al, 1996; Jares et al, 1997);
however, none of these studies have examined the biallelic
inactivation of the p16 and its relationship with the patients
clinicopathological characteristics or survival.
In this report, to investigate the role of the p16 genetic alter-
ations in head and neck tumours, we performed a comprehensive
analysis of the mechanisms involved in p16 inactivation, such as
mutations, hypermethylation, homozygous and heterozygous
deletions. We further investigated whether there was a relationship
between p16 inactivation and clinicopathological characteristics
and survival of the patients.
MATERIALS AND METHODS
Tissue samples
Paired tumour and normal tissue were obtained from 47 patients
with primary head and neck squamous cell carcinoma, before any
treatment, at the AC Camargo Hospital, São Paulo, Brazil.
Tumours consisted of squamous cell carcinomas localized to the
oral cavity (n = 25), oropharynx (n = 8), hypopharynx (n = 7) and
larynx (n = 7). Tumour samples were dissected to remove residual
normal tissue before freezing and storage in liquid nitrogen. To
determine the amount of residual normal tissue, sections of tumour
were stained with haematoxylin and eosin for histopathological
examination. The amount of normal cell contamination in each
tumour sample was estimated by the pathologist to not exceed
25%. The age of the patient at the time of operation ranged from
27 to 80 years (median 61). The study included a total of 40 males
and seven females. Information on smoking history and alcohol
intake was available from 36 and 31 patients respectively. Regular
alcohol intake was declared by 83% of the smokers. The clinical
stage of the patients was determined according to the UICC TNM
staging system and histopathological grade based on the WHO
classification.
DNA extraction
Tissue was ground to a powder using a Frozen Tissue Pulverizer
(Termovac), the powder was resuspended in 1 ml of lysis buffer
(10 mM Tris–HCl, pH 7.6, 1 mM EDTA and 0.6% sodium dodecyl
sulphate (SDS) and 100 mg ml–1 proteinase K, and incubated at
37° overnight. High molecular weight DNA was extracted with
phenol–chloroform and precipitated with ethanol.
LOH analysis
LOH for the chromosomal region 9p21–22 was analysed using
two polymerase chain reaction (PCR)-based polymorphic
markers, as described previously (Kwiatkowsky and Diaz, 1993;
Gyapay et al, 1994). Allelic losses were determined by densito-
metric scan (UltroScan XL; Pharmacia) as complete or partial if
the intensity of one allele was reduced by at least 40% in tumour
DNA as compared with normal DNA of the same patient. LOH
was scored for informative (heterozygous) patients only.
PCR – single-strand conformation polymorphism
analysis
Two sets of oligonucleotide primers were used to amplify exons
1 and 2 of the p16 gene, the primers used were the same as those
described by Okamoto et al. (1994) and Sun et al (1995). PCR
reactions were performed in 25-ml volumes using 50–100 ng of
genomic DNA template, 1 mM of each primer, 1.5 mM magnesium
chloride, 200 mM of each deoxynucleotide triphosphate, 0.1 mCi
of [a32P-dCTP] (Amersham, specific activity, 3000 Ci mmol–1),
50 mM potassium chloride, 10 mM Tris–HCl pH 8.0, and 0.5 unit
of Taq DNA polymerase (Pharmacia, NJ, USA). Samples were
overlaid with mineral oil and amplified for 35 cycles of denatura-
tion, annealing and extension optimized for each primer set. The
reactions were performed with an automated Thermal Cycler
(Perkin-Elmer 580). Amplification products (1 ml) were diluted
tenfold in a buffer containing 95% formamide, 20 mM EDTA,
0.05% bromophenol blue and 0.05% xylene cyanol, heated at
83°C for 5 min and applied (3 ml per lane) on two 6% polyacl-
amide non-denaturing gel, one containing 5% glycerol and the
other 10% glycerol.
Electrophoresis was performed at 6 W for 14–16 h at room
temperature with two cooling fans. Band shift mobility was
detected by autoradiography of dried gels using Kodak X-Omat
XAR film with an intensifying screen for 12–48 h at –70°C.
Direct DNA sequencing
DNA samples with suspected p16 mutations as judged by single-
strand conformation polymorphism (SSCP) gels were amplified
using the same primers. The PCR products obtained were purified
using Wizard PCR Preps kit (Promega Corporation, Madison, WI,
USA) according to the manufacturer’s procedure. Three to 5 ml of
ten out of the purified DNA was subjected to a dideoxy chain
termination reaction using a double-stranded DNA Cycle
Sequencing kit (Pharmacia) for both sense and antisense primers.
Sequencing reaction products were denatured and resolved on 6%
denaturing urea/polyacrylamide gels. Gels were fixed for 15 min
in a 10% methanol/ 10% acetic acid solution, dried and exposed to
X-ray film overnight.
Homozygous deletion analysis
By Southern blot: high molecular weight DNAs (10 mg) were
digested with EcoRI restriction endonuclease according to
manufacturer’s specification. Digested DNA samples were
electrophoresed in 0.8% agarose gels with ethidium bromide and
transferred to nylon membranes, which were hybridized with the
PE1 probe described by Merlo et al (1995) labelled with
[32P]dCTP by random priming. Membrane hybridizations and
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1993). Southern blots were stripped of probe by sodium hydroxide
treatment and reprobed with a b-microglobulin probe to evaluate
the amount of DNA loaded onto each lane. Scanning densitometry
of the autoradiographies was carried out to quantify the signal
intensity of the hybridized bands using an UltroScan XL
(Pharmacia). By PCR, the same primers used for the SSCP
analysis were used to investigate the occurrence of homozygous
deletions. PCR reactions were performed using 100 ng of genomic
DNA in the same conditions described for the SSCP analysis but
with 24 cycles. Genomic DNA from the breast cancer cell line
MCF-10F was used as positive control for homozygous deletion.
PCR products were analysed on a 2% agarose gel.
PCR-methylation assay
p16 methylation status was examined using the combination of
digestion of genomic DNA with methylation-sensitive restriction
enzymes and PCR amplification. Genomic DNA (1 mg) was
digested with 10 units of HpaII, CfoI or SmaI overnight according
to manufacturer’s instructions. In order to ensure complete diges-
tion this step was repeated. Digested DNA samples were amplified
by PCR using primers specific for exon 1 of the p16 gene (Kamb et
al, 1994a) and for a microsatellite marker (D9S145, 9q13–21.2),
used as PCR control (Furlong et al, 1992). PCR was performed
under the same conditions described for the SSCP analysis,
without [a32P-dCTP], for 35 cycles of 94°C for 1 min, 55°C for
1 min, 72°C for 1 min and a final extension at 72°C for 5 min. The
PCR products were analysed by electrophoresis on 2% agarose
gels.
Statistical methods
Analyses of statistical significance between the p16 genetic alter-
ations, and the clinicopathological characteristics of the patients
were performed by the c2 test and Fisher exact test for frequency
data in contingency tables. Disease-free survival and overall
survival probabilities were calculated based on the Kaplan–Meier
product limit technique (Kaplan and Meier, 1958).
RESULTS
Paired normal and tumour DNA from 47 patients with head and
neck cancer were examined for the occurrence of p16 genetic
alterations (Table 1). Exons 1 and 2 of p16 were analysed for
mutations by PCR-SSCP. Seven out of the 47 cases analysed
showed evidence for p16 mutations (exon 1, three cases; exon 2,
four cases). DNA samples showing electrophoretic band shift
mobility were re-amplified and the product purified and used
directly for sequencing. Sequencing revealed the presence of six
mutations and one intronic polymorphism. Figure 1 shows repre-
sentative example of the sequencing analysis. Sequencing results
are summarized in Table 2. The p16 mutations observed included
three mis-sense mutations (exon 1, codon 16, CTG®CCA,
Leu®Pro; exon 2, codon 78, CTC®CAC, Leu®His; and exon 2,
codon 114, CCC®CTC, Pro®Leu), one frameshift mutation
(exon 2, codon 85, 1 bp insertion), one non-sense mutation (exon
2, codon 80, CGA®TGA, Arg®Stop) and one intronic mutation
(intron 1, G®T; splicing alteration). All tumours with mutations
were advanced stage tumours (two stage III and four stage IV),
two in the oral cavity, two in the larynx and two in the
hypopharynx.
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Table 1 p16 genetic alterations observed in head and neck tumours
Number of Alterations
Analyses cases analysed observed
PCR-SSCP Exon 1 47 2/47 (6%)
Exon 2 47 4/47 (8%)
Methylation assay Exon 1 47 22/47 (47%)
LOH IFNA 47 11/28 (39%)
D9S171 47 14/27 (52%)
Southern blot 47 1 case
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Figure 1 Sequencing analysis of p16 exons 1 and 2 mutations in head and
neck tumours. Case CP68 and CP51 showed a mis-sense mutation in exon
2 (codon 78, CTC®CAC, Leu®His) and in exon 1 (codon 16, CTG®CCA,
Leu®Pro) respectively. Case CP56 shows an intronic polymorphism
IFNA
D9S171
CP 94
NT
CP 12
NT
CP8
NT
CP 75
NT
N  T N  T N  T N  T
Figure 2 Representative autoradiographs from loss of heterozygosity
analysis of chromosome 9p in head and neck tumours. DNAs extracted from
tumour (T) and corresponding normal (N) tissues were analysed using
microsatellite markers IFNA and D9S171 as indicated on the left of the
autoradiographs. Top, case numbers; arrow, allele showing reduction in
intensityThe occurrence of homozygous deletions was investigated by
Southern blotting and PCR. Only one tumour DNA sample
showed reduction (40%) in the intensity of the bands in the auto-
radiograms when compared with the corresponding normal DNA
(data not shown), suggesting the occurrence of homozygous dele-
tion.
LOH was analysed by PCR using two microsatellite markers,
IFNA and D9S171, flanking the p16 locus (CDKN2). IFNA and
D9S171 showed allelic loss in 11/28 (39%) and 14/27 (52%)
informative cases respectively. Of the 32 informative tumours
examined 17 (53%) showed LOH for at least one of the markers
analysed. Representative results of the LOH analysis are shown in
Figure 2.
Methylation status of the CpG sites in exon 1 of the p16 gene
was examined using methylation-sensitive enzymes (HpaII, SmaI
and CfoI) and PCR amplification. Hypermethylation was detected
in 22 of 47 cases analysed (47%). Tumours with different patterns
of DNA methylation are shown in Figure 3. The absence of a
310 bp PCR product for exon 1 of the p16 gene indicates that the
HpaII, SmaI and/or CfoI restriction sites were unmethylated and
had been cleaved (case CP44T). However, the presence of the
310 bp PCR product resistant to digestion with methylation-
sensitive enzymes indicates the occurrence of de novo methylation
(cases CP13T and CP88T).
In the present study, taking in account only the informative
patients,  p16 biallelic inactivation was found in 59% (19/32) of the
head and neck tumours analysed; 13 cases with hypermethylation
and LOH; four cases with mutation and LOH; and two informative
cases with retention of heterozygosity showing concomitant
hypermethylation and mutation. In addition, homozygous deletion
was observed in one case.
In the series of tumours examined no correlations were found
between p16 genetic alterations (mutation, hypermethylation and
LOH together or alone) and age, tumour site, TNM staging,
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Table 2 Summary of the p16 mutations observed in head and neck tumours
Case Exon Codon Mutation Effect
CP 1 Intronl G®T Splicing alteration
CP 16 2 80 CGA®TGA Arg®Stop
CP 28 2 85 1 bp insertion Frameshift
CP 30 2 114 CCC®CTC Pro®Leu
CP 51 1 16 CTG®CCA Leu®Pro
CP 68 2 78 CTC®CAC Leu®His
Table 3 Associations between p16 biallelic inactivation and the
clinicopathological characteristics of 47 patients with head and neck tumours
biallelic inactivation
Characteristics Categories N No Yes P-valuea
Age ≤ 50 years 9 5 4
> 50 years 38 25 13 0.57
Gender Male 40 25 15
Female 7 5 2 0.65
Tumour site Oral cavity 24 16 8
Oropharynx 8 4 4
Hypopharynx 7 4 3
Larynx 7 5 2 0.75
Lymph-node status Negative 22 13 9
Positive 25 17 8 0.53
Histological gradeb I3 1 1 9 1 2
II 10 7 3
III 6 4 2 0.87
Tumour stagec I1 – 1
II 5 3 2
III 20 15 5
IV 21 12 9 0.31
Tobacco consumption Smoker 36 23 13
Non-smoker 6 5 1 0.33
Alcohol consumption Drinker 31 20 11
Non-drinker 10 8 2 0.35
aChi-square test; bUICC TNM staging system; cWHO classification. 
p16
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Exon 1 p16 Exon 1 p16 Exon 1 p16
CP 44N CP 44T CP 13N CP 13T CP 88N CP 88T
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Figure 3 Analysis of methylation status of the CpG island in exon 1 of the p16 gene in head and neck tumours. The presence of a 310 bp PCR product after
digestion with HpaII, SmaI or CfoI indicates de novo methylation. A representation of the methylation status of the restriction sites in each case is shown on the
right. Case CP13T showed methylation at the HpaII and SmaI sites; Case CP88T showed methylation at HpaII, SmaI and CfoI sites; and Case CP44T showed
complete digestion at all restriction sites examined indicating absence of methylationhistological differentiation, positive lymph nodes or tobacco and
alcohol consumption of the patients (Table 3). In addition, no
differences in survival were found between patients stratified for
p16 hypermethylation or biallelic inactivation (median survival
36.71 months) (Figure 4).
DISCUSSION
Mutations, homozygous and heterozygous deletions and hyper-
methylation are the most common genetic events associated with
the p16 tumour suppressor gene inactivation. In the present study,
we found evidence of p16 inactivation in a high proportion (59%)
of the head and neck tumours examined.
Thirteen per cent of the tumours analysed were found to have
p16 mutations. The base substitutions in exon 2 were at codons 78,
80 and 114 located within the ankyrin domains (Serrano et al,
1993). Mutations at codon 114 involved a highly conserved
proline (P114) in the fourth ankyrin domain. Hence, the affected
codons involve amino acids in domains which are likely to be
essential for p16 biological activity. Although, the exon 2 is shared
by p16ink4a and p19arf (Serrano et al, 1996; Chin et al, 1998)
experimental evidence indicates that mutations at exon 2 of the
CDKN2A affects p16ink4a only (Arap et al, 1997). In addition, exon
1b of the CDKN2A appears to be critical for p19arf function, both
binding of p19arf to p53 and cell cycle arrest requires exon 1b but
not exon 2 (Quelle et al, 1997; Kamijo et al, 1998). Furthermore,
in the present study we have observed a point mutation in the
acceptor site of intron 1 and a missense mutation in exon 1a
(codon 16) implicating p16ink4a as the major target of inactivation
in the head and neck tumours analysed.
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Figure 4 Kaplan–Meier estimates of disease-free (A) and overall (B) survival in head and neck patients stratified according to the p16 biallelic inactivation.
n n, patients with tumours showing p16 biallelic inactivation; l l, patients with tumours without p16 biallelic inactivation (A, P = 0.74; B, P = 0.73)Although homozygous deletions has been reported to be an
important mechanism of p16 inactivation in several human
cancers, including head and neck tumours (Reed et al, 1996), in
our series of tumours only one tumour showed evidence for
homozygous deletion. Despite the fact that Southern blot and PCR
analyses were used to examine the occurrence of homozygous
deletions, we cannot rule out the possibility that normal cell
contamination could account for the exquisitely low frequency of
homozygous deletion found in the present study.
LOH and DNA hypermethylation were observed in 53% and
47% of the cases analysed respectively, representing the major
mechanisms which may lead to p16 inactivation. In total 59%
(19/32) of the informative patients with head and neck tumours
examined showed evidence of p16 biallelic inactivation. Overall,
20% (4/20) of the cases with biallelic inactivation showed muta-
tion and hypermethylation, 10% (2/20) showed mutations and
LOH, 65% (13/20) showed hypermethylation and LOH and 5%
(1/20) showed homozygous deletion. These observations indicate
that LOH and hypermethylation leading to p16 inactivation is
common in head and neck tumours. These results are similar to
those of Wong et al (1997) in oesophageal adenocarcinomas and
corroborate with previous studies that have demonstrated high
incidence of p16 hypermethylation in head and neck tumours
(El-Naggar et al, 1997; Gonzáles et al, 1997).
To assess the prognostic potential of p16 inactivation in the
development of head and neck tumours the genetic alterations
observed (alone and in combination) were correlated with the
clinicopathological characteristics (such as age, tumour size,
lymph node status, clinical stage, histological grade) and patient
outcome. Our study failed to demonstrate any correlation between
p16 inactivation and these clinicopathological characteristics or
survival of the patients. LOH of chromosomal region 9p21 has
been postulated to be an early event in head and neck cancer
(Califano et al, 1996) and p16 inactivation has been detected in
preneoplastic lesions of the larynx and oral cavity (Gallo et al,
1997; Papadimitrakopolou et al, 1997). Our failure to find prog-
nostic significance for the p16 genetic alterations might suggest
that p16 inactivation is an early event in carcinogenesis in a
subgroup of head and neck tumours but with little or no influence
on further tumour progression. The high frequence of tumours
with p16 biallelic inactivation observed here provides further
support to previous report (Reed et al, 1996) that p16 tumour
suppressor gene does play an important role in the tumorigenic
process of the head and neck. This hypothesis is also supported by
observations that p16 expression inhibits growth in cell lines
derived from squamous cell carcinomas of the head and neck
(Liggett et al, 1996). However, whether p16 inactivation is an
important predictor for prognosis and disease outcome needs to be
clarified by further molecular epidemiological studies.
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